The FDA has officially withdrawn approval for the pregnancy drug Makena, based on postmarketing studies which failed to show it provided any benefits to pregnant mothers.
The makers of the controversial pregnancy drug, Makena, have decided to withdraw the medication from the market after health experts determined it provides no benefit to pregnant women or their…
A federal judge has cleared Valsartan NDMA lawsuits to proceed after rejecting a call by defendants to reconsider the admissibility of plaintiffs' expert witnesses following the recent dismissal of Zantac…
Health experts say problems with the accelerated drug approval program have led to Makena and other ineffective drugs staying on the market even after its proven they do not work.
Plaintiffs involved in Zantac litigation have submitted new evidence from a recently published study which links Zantac use to four different types of cancer.
State courts are being flooded with thousands of lawsuits over Zantac cancers which have not been included in the consolidated federal Multidistrict Litigation.
Daubert hearings for expert witnesses slated for Zantac cancer trials will begin on September 21.
A Zantac lawsuit was settled by generic drug makers, and dropped against GSK just days before trial was set to begin in an Illinois state court.
Ahead of the first Zantac lawsuit trials, slated to begin next year, investors sold off Sanofi, GlaxoSmithKline and Pfizer stocks, anticipating massive court losses and costs.
The first California Zantac bellwether trials have been pushed back to February 2023.
